Briefing on the Fundamentals of Agilent Technologies

By Susan Ramirez • Wednesday, June 25 10:07 • Permanent Link

More and more people are talking about Agilent Technologies over the last few weeks. Is it worth buying the Biotechnology stock at a price of $117.79? Only time will tell. The information below will give you a basic idea of what this investment may entail:

Agilent Technologies has moved -11.6% over the last year, and the S&P 500 logged a change of 11.2%
A has an average analyst rating of buy and is -13.71% away from its mean target price of $136.51 per share
Its trailing earnings per share (EPS) is $4.06
Agilent Technologies has a trailing 12 month Price to Earnings (P/E) ratio of 29.0 while the S&P 500 average is 29.3
Its forward earnings per share (EPS) is $5.65 and its forward P/E ratio is 20.8
The company has a Price to Book (P/B) ratio of 5.45 in contrast to the S&P 500's average ratio of 4.74
Agilent Technologies is part of the Industrials sector, which has an average P/E ratio of 24.03 and an average P/B of 2.89
A has reported YOY quarterly earnings growth of -28.6% and gross profit margins of 0.5%
The company has a free cash flow of $1.05 Billion, which refers to the total sum of all its inflows and outflows of cash over the last quarter
Agilent Technologies, Inc. provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The company operates in three segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; inductively coupled plasma optical emission spectrometry instruments; raman spectroscopy; laboratory software; information management and analytics; laboratory automation and robotic systems; dissolution testing; and vacuum pumps, and measurement technologies. This segment also offers GC and LC columns, sample preparation products, custom chemistries, and laboratory instrument supplies. The Diagnostics and Genomics segment provides genomics, contract manufacturing and research and development, pathology, companion diagnostics, reagent partnership, and biomolecular analysis businesses; and cell analysis plate based assays, flow cytometers, real-time cell analyzers, cell imaging systems, microplate readers, and related consumables. The Agilent CrossLab segment provides various services, including repairs, parts, maintenance, installations, training, compliance support, software as a service, asset management, and consulting services. The company markets its products through direct sales, distributors, resellers, manufacturer's representatives, and electronic commerce. Agilent Technologies, Inc. was incorporated in 1999 and is headquartered in Santa Clara, California.

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.